by
The European Society of Child and Adolescent Psychiatry (ESCAP) urged healthcare providers ‘not to promote experimental and unnecessarily invasive treatments with unproven psycho-social effects.’
(LifeSiteNews) — A major European psychiatric organization has warned doctors against promoting “experimental” transgender “treatments” to gender-confused children and adolescents
The European Society of Child and Adolescent Psychiatry (ESCAP) published a policy statement urging healthcare providers “not to promote experimental and unnecessarily invasive treatments with unproven psycho-social effects and, therefore, to adhere to the ‘primum-nil-nocere’ (first, do no harm) principle.”
The scientists of ESCAP highlighted the “poor reliability and instability of a gender dysphoria diagnosis in a specific child over time” and the “possible effects of the decisions to block puberty or preventing medical transitioning on a child’s psychosocial development.”
The report also stressed that “research findings are published solely on the grounds of quality criteria and not based on their findings.” In a post on X, formerly known as Twitter, the Society for Evidence-Based Gender Medicine (SEGM) interpreted this statement to mean that many recent studies reporting favorably about so-called “gender transition” are “deeply methodologically flawed.”
While the ESCAP report remained open to the possibility that some children might benefit from so-called “gender-affirming care,” it underscored the lack of quality research to accurately determine the risk-benefit ratio of interventions such as hormone blockers and mutilating surgeries.